Addex Therapeutics Ltd (SWX: ADXN)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 7.24M |
| Revenue | 1.38M |
| Net Income | -11.24M |
| Shares Out | 98.31M |
| EPS | -0.13 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 154,931 |
| Open | 0.0736 |
| Previous Close | 0.0736 |
| Day's Range | 0.0722 - 0.0762 |
| 52-Week Range | 0.0362 - 0.2600 |
| Beta | 1.98 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 11, 2024 |
About Addex Therapeutics
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB... [Read more]
News
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Geneva, Switzerland, September 4, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulato...
S&P 500 Edges Higher; American Woodmark Shares Slide
U.S. stocks traded mixed toward the end of trading, with the S&P 500 gaining around 0.2% on Tuesday. The Dow traded up 0.01% to 41,242.33 while the NASDAQ rose 0.24% to 17,768.84. The S&P 500 also ros...
Crude Oil Dips; Addex Therapeutics Shares Spike Higher
U.S. stocks traded mostly lower midway through trading, with the Dow Jones index falling around 0.2% on Tuesday. The Dow traded down 0.16% to 41,175.13 while the NASDAQ fell 0.03% to 17,720.68. The S&...
Crude Oil Dips; Addex Therapeutics Shares Spike Higher
U.S. stocks traded mostly lower midway through trading, with the Dow Jones index falling around 0.2% on Tuesday.
Why Addex Therapeutics stock skyrocketed 70% on Tuesday
Addex Therapeutics Ltd (NASDAQ: ADXN) opened about 70% up this morning after making significant strides in its GABAB-positive allosteric modulator research. The clinical-stage pharmaceutical company h...
Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder
Tuesday, Addex Therapeutics Ltd (NASDAQ: ADXN) stock is trading higher with a session volume of 3.79 million versus the average volume of 4.16K as per data from Benzinga Pro . Addex Therapeutics and ...
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 27, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of...
Addex's Partner Discontinues ADX71149 development in Epilepsy
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio ...
Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a por...
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)
Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric mo...
Addex Shareholders Approve All Resolutions at Annual General Meeting
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 1, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulatio...
Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024 .
Addex Convenes Annual General Meeting 2024
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portf...
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulator...
Addex to Present at Bio€quity Europe 2024
Geneva, Switzerland, May 8, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO,...
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio...
Addex to Present at the Swiss Biotech Day 2024
Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that C...
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024 Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical p...
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that i...
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
Addex receives CHF5M and 20% share of Neurosterix Perceptive Advisors leads $63M investment into Neurosterix Addex contributes portfolio of preclinical neuroscience assets and allosteric modulator s...
Addex to Present at the Bio-Europe Spring 2024 Conference
Geneva, Switzerland, March 14, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today tha...
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 31, 2024 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug d...
Addex to Present at the Swiss Equities Baader Conference
Geneva, Switzerland, January 9, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today a...
Addex to Present at Biotech Showcase™ 2024
CEO to provide update on allosteric modulator pipeline clinical and preclinical development Geneva, Switzerland, January 5, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceu...
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 20, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modu...